Sarcomas | Specialty

The OncLive Sarcomas/TGCT condition center page is a comprehensive resource for clinical news and expert insights on tenosynovial giant cell tumor (TGCT), soft tissue sarcoma, gastrointestinal stromal tumor, Ewing sarcoma, and more. This page features news articles, interviews in written and video format, and podcasts that focus on unmet needs, treatment advances, and ongoing research in sarcomas and TGCT.

Next-Generation Sequencing Reveals Potentially Actionable Mutations in Sarcoma

February 18th 2021

February 18, 2021 — The use of next-generation sequencing demonstrated that 34% of patients with sarcoma had potentially actionable mutations.

Dr. Dhir on Ongoing Research Efforts in Epithelioid and Synovial Sarcoma

February 16th 2021

Aditi Dhir, MD, discusses ongoing efforts in epithelioid and synovial sarcoma.

NBTXR3 Activity in Soft Tissue Sarcoma Could Be Replicated in Other Cancers

February 15th 2021

NBTXR3, a novel radioenhancer, is showing intriguing response rates in adult patient with soft tissue sarcoma, paving a path for the innovative therapy not just in sarcomas, but other tumor types, as well.

Risk-Based Therapy for Local Control in Pediatric Non-Rhabdomyosarcoma Soft Tissue Sarcoma Shows Promise

February 11th 2021

R. Lor Randall, MD, discusses the intriguing risk-stratification–based trial in NSTRS and how the findings can be used to guide treatment decisions in this pediatric population.

Dr. Dhir on Risk-Based Stratification in Epithelioid and Synovial Sarcoma

February 10th 2021

Aditi Dhir, MD, discusses risk-based stratification in patients with epithelioid and synovial sarcoma.

Dr. Wagner on Responses Achieved With Nivolumab/Ipilimumab in Angiosarcoma

February 9th 2021

Michael Wagner, MD, discusses responses achieved with nivolumab plus ipilimumab in patients with angiosarcoma.

Dr. Dhir on Diagnostic Challenges in Sarcoma

February 5th 2021

Aditi Dhir, MD, discusses the challenges of diagnosing patients with sarcoma.

Dr. Wagner on Future Research Efforts in Sarcoma Subtypes

February 4th 2021

Michael Wagner, MD, discusses future research efforts in sarcoma subtypes.

Dr. Wagner on the Potential for Immunotherapy in Angiosarcoma

February 3rd 2021

Michael Wagner, MD, discusses the potential use of immunotherapy in patients with angiosarcoma.

Dr. Murphy on the Utility of Pazopanib Plus SBRT in Pediatric Sarcoma

January 29th 2021

Erin Murphy, MD, discusses the utility of pazopanib plus stereotactic body radiation therapy in pediatric sarcoma.

FDA Grants Orphan Drug Designation to Ilixadencel for Soft Tissue Sarcoma

January 26th 2021

January 26, 2021 - The FDA has granted the cell-based, off-the-shelf immune primer ilixadencel an orphan drug designation for use as a treatment option in patients with soft tissue sarcoma.

Bioengineered Models Could Improve Understanding of Bone Cancer, Metastases

January 26th 2021

R. Lor Randall, MD, FACS, discusses the rationale and motivation behind tissue-engineered platforms and how they could significantly impact the understanding of how cancer arises in or metastasizes to bone.

Larotrectinib Elicits Durable Responses, Extends Survival in TRK+ Sarcomas

January 11th 2021

January 11, 2021 - Larotrectinib was found to induce a high response rate with long durability and improve survival in patients with TRK-positive sarcomas, according to results from an analysis of 3 clinical trials.

Dr. Dhir on Modifying Treatment for Adults Versus Pediatric Patients With Epithelioid Sarcoma

January 6th 2021

Aditi Dhir, MD, discusses modifying treatment for adults versus pediatric patients with epithelioid sarcoma.

TP53, NF1 Among Genetic Variants Identified as Precursors to Pediatric Rhabdomyosarcoma

January 6th 2021

Germline predisposition variants associated with cancer susceptibility syndromes can underlie the genetic risk for rhabdomyosarcoma, indicating that germline testing should be performed in accordance with RMS subtypes and irrespective of age.

Dr. Trent on the Role of Adjuvant Imatinib in GIST

January 6th 2021

Jonathan C. Trent, MD, PhD, discusses the role of adjuvant imatinib in gastrointestinal stromal tumors.

Ripretinib Under Investigation for Second-Line GIST in Phase 3 INTRIGUE Trial

January 5th 2021

January 5th, 2021 - Ripretinib is under investigation as a second-line treatment in patients with gastrointestinal stromal tumor versus sunitinib in the phase 3 INTRIGUE trial, which recently completed its target enrollment.

Spotlighting Management Strategies Across Sarcoma Subtypes

January 4th 2021

Faculty of a recent Institutional Perspectives in Cancer webinar on sarcoma, hosted by Sylvester Comprehensive Cancer Center, share updates in the management of gastrointestinal stromal tumor, epithelioid and synovial sarcoma, and tenosynovial giant cell tumor.

Phase 2/3 RINGSIDE Trial of AL102 Can Proceed in Desmoid Tumors

January 4th 2021

January 4, 2021 — The pivotal phase 2/3 RINGSIDE trial, which is evaluating the potent, selective oral gamma secretase inhibitor AL102, has been permitted to proceed and can potentially be used as a registrational study for adolescent and adult patients with desmoid tumors.

FDA Grants Annamycin Orphan Drug Status for Soft Tissue Sarcomas

December 29th 2020

December 29, 2020 - The FDA has granted an orphan drug designation to Annamycin for the treatment of patients with soft tissue sarcomas.